This study is a collaboration with the University Hospital Centre of Montpellier, of Lyon, and of Paris. We are grateful to Pr. Eric Assenat, Pr. Edouard Tuaillon, Pr. Marianne Ziol, Dr. Marie Dupuy, and Dr. Séverine Tabone-Eglinger for their precious contribution to this work. We have previously shown that our
Animal testing plays a critical role in gaining important knowledge needed to thoroughly evaluate the products towards reducing the health risks and sufferings to human and animals. The current regulatory framework of various countries and FDA permits, encourages, and supports the use of new alternative methods to animal testing that
Our CEO Dr Hong Tuan DUONG, discussed the use of individual-centric spheroid model to decipher the initiating-mechanism of immune mediated idiosyncratic drug-induced liver injury by presenting the poster “Dissecting the idiosyncratic drug-induced liver injury (iDILI)-initiating mechanism using the individual-centric model: the role of the innate immune response” While Dr Sara
We are pleased to announce that PredictCan Biotechnologies joined the North American 3Rs collaborative as a bronze-level initiative member. The 3Rs collaborative is a non-profit organization that facilitates collaborative opportunities between academics, pharmaceutical companies, contract research organizations, government organizations, and regulatory agents to refine, reduce, and replace animals in research.
We are pleased to announce that our original research article on the capability of individual-centric spheroid model to detect immune-mediated idiosyncratic DILI at therapeutic doses has just been published in Frontiers in Pharmacology, section Predictive Toxicology. « Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury:
PredictCan Biotechnologies is pleased to announce the appointment of Professor Jean-François DUFOUR to its Scientific Advisory Board. Professor DUFOUR is a world-leading hepatologist focusing on Metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). He published more than 350 scientific publications and is an associate editor of GUT. Professor DUFOUR is
